Related Experiment Videos
Expression of interferon alpha/beta receptor in human hepatocellular carcinoma
1Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Japan.
Insights
Interferon-alpha/beta receptor (IFNalpha/betaR) expression is elevated in liver conditions like chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Higher IFNalpha/betaR levels in HCC correlate with poorer tissue differentiation.
Area of Science:
- Hepatology
- Immunology
- Oncology
Background:
- Interferon-alpha (IFNalpha) mediates antiproliferative and immunoregulatory functions via the interferon-alpha/beta receptor (IFNalpha/betaR).
- Understanding IFNalpha/betaR expression is crucial for liver disease and hepatocellular carcinoma (HCC) research.
Purpose of the Study:
- To investigate the immunohistochemical expression of IFNalpha/betaR in hepatocellular carcinoma (HCC) and pre-cancerous liver conditions.
- To correlate IFNalpha/betaR expression with clinicopathological features of HCC.
Main Methods:
- Immunohistochemical analysis of IFNalpha/betaR expression.
- Examination of liver tissues including normal liver, chronic hepatitis, cirrhosis, dysplastic nodules, and HCC.
- Correlation analysis with clinicopathological parameters.
Main Results:
- IFNalpha/betaR levels were increased in chronic hepatitis and cirrhosis compared to normal liver.
- All dysplastic nodules exhibited moderate to high IFNalpha/betaR expression.
- In HCC, 26% showed high, 38% moderate, and 35% no or faint IFNalpha/betaR expression.
- A significant correlation was found between IFNalpha/betaR expression and HCC differentiation (P=0.0008).
Conclusions:
- IFNalpha/betaR is expressed in chronic hepatitis, liver cirrhosis, and HCC.
- IFNalpha/betaR expression in HCC is significantly associated with tumor differentiation.
- No correlation was observed between IFNalpha/betaR expression in HCC and patient survival outcomes.
Abstract:
Interferon-alpha (IFNalpha) plays a crucial role in the antiproliferation and immunoregulatory activity through the specific cell surface receptor, interferon-alpha/beta receptor (IFNalpha/betaR). We examined the immunohistochemical expression of IFNalpha/betaR in 91 hepatocellular carcinoma (HCC), HCV-related chronic hepatitis (n=38) and cirrhosis (n=53), dysplastic nodules (n=5), and normal liver (n=9). The level of IFNalpha/betaR increased in chronic hepatitis and cirrhosis compared with normal liver. All the dysplastic nodules showed moderate or high expression. In HCCs, 26% (24/91) of patients showed high IFNalpha/betaR expression while the remaining 38% (35/91) showed moderate, and 35% (32/91) no or faint expression. Clinicopathological survey demonstrated a significant correlation between IFNalpha/betaR expression and differentiation of carcinoma (P=0.0008) although there was no correlation between IFNalpha/betaR expression in HCC and survival or disease-free survival. Thus, IFNalpha/betaR was expressed not only in chronic hepatitis or liver cirrhosis but in HCC and its expression was significantly correlated with tissue differentiation of carcinoma.